Maxim Group analyst Jason McCarthy maintained a Buy rating on Biocept (BIOC – Research Report) yesterday and set a price target of $7.00. The company’s shares closed last Thursday at $2.05, close to its 52-week low of $1.78.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.4% and a 16.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biocept with a $7.00 average price target.
Biocept’s market cap is currently $34.53M and has a P/E ratio of 13.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.
Read More on BIOC: